Biovica International AB (publ)

Hello everyone and welcome to the Bayerika Q1 interim report. Today it will be me Anders Sri Lander together with my CFO Anders Morén and Hector Tamburini, head of US operations and Henrikh Vinter, head of business development and pharma services, who will be presenting and the agenda will be a short introduction about the company will focus on the Q1 highlights Anders will go into the financials, Hector will give an update about the US progress and Henrikh will do the same for pharma services and at the end there will be a summary and we'll open up for a Q&A session. The way the Q&A session will work is that first we will let our analyst, financial analyst in, which you see here on the screen, Joanne from Redeye and we have and Luisa from Kempen also. You can also submit questions in the chat window and if we have time we will limit this to one hour, we will answer these questions from the chat as well in the webcast and all questions that we can answer we will also answer in writing and add it as an appendix to the presentation that will be uploaded after the meeting. So if I start with a very short introduction of BioVika, what we do, we have our product Divitum that measures cell proliferation. Cell proliferation of course is essential for us humans and it's also a hallmark of cancer, how cancer grows. Divitum has shown to be an excellent tool both before start of treatment to provide prognosis of how the aggressive treatment is and how the outcome for the patient will be but also and that's our focus area to be an excellent monitoring tool for patients being on treatment. This is something there's a great demand and need for being able to provide better monitoring for patients currently being on treatment. We have data showing that we can provide a shorter time to follow up progression. We're talking weeks rather than months and of course that's beneficial for the patient that more quickly can get a confirmation that they are on an effective treatment or if not that we can do something about it for instance change those or even change treatment. This is something also that's been highlighted by the FDA that has initiatives like the Project Optimus that wants to turn the standard from maximizing the tolerated dose to the most efficient treatment and for such a scenario you need efficiency biomarkers for monitoring just what we can provide with Divitum. So we have a product that can provide the excellent value both for patients being on treatment but also health care providers and also for health economics because treatments within this area are priced at more than ten thousand dollars per month and patients so of course using those resources well is essential also for health economics. So this what I'm saying has been in many clinical trials over 30 at this point has been published in these trials more than 5,000 patients been included and the majority is in within our initial focus area which is the breast cancer area. These clinical trials has been performed by some of the leading institutions and oncologists in the world. In the US we have a Mayo Clinic, Dana Farber, Washington University and Johns Hopkins for instance, Baylor College those are all examples of institution and oncologists that we have been working with to perform these clinical trials and then in Europe we also are working with leading institutions and breast cancer groups. This is of course important because that's an excellent way for us to get the message across from these leading colleges that present the data on as

keynote speakers on conferences etc. The potential for the product is

very large in this example we are focusing on the metastatic breast cancer area where we are currently focused in our commercial efforts in US and in the major countries in Europe including the Nordics is our focus area. We are also active supporting pharma. Pharma can benefit from using our productivity when they develop new treatments within cancer. It's of course important to getting the feedback whether the treatment is efficient enough and you can use it as input for designing and following up on clinical trials and our ambition is to extend these collaborations into co-development projects resulting in new products tailored complementary to new treatments so-called companion diagnostics. This is an area that will be covered by Henrik Winter in the presentation but there's also potential outside the two areas that we are currently most active within both in earlier phases of breast cancer but also in other indications outside of breast cancer where we have data supporting the value and it's the same diagnostic challenge that we can address in breast cancer. You see that outside of breast cancer area as well and in that setting the immunochekpoint inhibitor area is a very interesting area as well where we can add value and also we have a path and process pending

which Henrik will talk a little bit more about. If I were to summarize the highlights from

the quarter, I'd like to start with the sales in the US. We've seen a trend now over several quarters. We started on really low levels of course but now we're building up 50% increase since last quarter and that's despite reducing the volume of our existing accounts but also attracting new both institutions and prescribers so the business is developing well in the US market. When it comes to our collaborations with pharma we see the same positive underlying trend that we've been seeing for years now. We've building up a portfolio of both pharma companies and using in several clinical trials and projects and there's a high demand and we see growth in both number of pharma companies and projects being started so that's very positive. One setback was expectation to projects that was expected to start during Q1 that was pushed forward to Q2 and also thereby pushing the revenues forward one quarter so we will see those in Q2 instead which of course is good. If you look at the financials we announced in April earlier this year that we do a reorganization with the purpose of reducing or improving our cash flow and now we see the results here in the first quarter an improvement by eight million Swedish versus the same period previous fiscal year and in addition to that we performed a direct issue where we had a European family office as well as a couple of Swedish investors that took part adding 16.4 million Swedish initially and there's an option to add another seven and a half in April next year so further strengthening

our financial position.

And

if we move

into the significant events for the quarter we continued to divotum to continue to prove itself in clinical trials at this time it was a Spanish group GAYCAM that presented the results on the CDK46 inhibitor on ASCO, ASCO being the world's largest cancer conference so big impact that's important the GAYCAM group is a leading group in Spain also setting the guidelines and has big impact so that helps us in that -to-market work that we have that and with our partner Palex that is in the process of introducing the test to the Spanish market. Also another so-called master service agreement for a US company developing a new CDK inhibitor we signed and Henrik will update you about where we stand with the entire portfolio there and then of course we had our general meeting extra general meeting to implement a new incentive program a long-term incentive program which is very positive to see that the board of directors and the employees in Sweden and Denmark has participated so it's oversubscribed so very grateful for that commitment and direct issue I already talked about. That was my introduction Anders will go now a little bit more into details and provide some numbers on the quarter that we just are

reporting. Anders let's switch place.

Thank you Anders. Yes moving into the Q1 net sales numbers on the right hand side you have the Q1 sales this quarter this year we ended up on 1.7 million which is in line with what we had Q1 previous year however it's important to understand what's going on below the surface here it's not just 1.7 million compared to 1.7 million as Anders said the US sales has really developed well we had you see a tiny bit of lilac colour there 13 000 previous year we have 627 000 this year so it's it's a huge improvement year over year. As Anders also said the pharma service business which are the two other revenue or product lines that we are selling currently is also developing very well in terms of interest of the product and our services however the nature of clinical trials and pharma development is always interesting and there are quite frequently happening that these are delayed rather than pushed forward. The important thing to remember here is that we haven't seen any cancellations or work orders or master service agreements on the other hand we have actually signed more master service agreements and more work orders during the quarter. Zooming in on the US sales this is in dollars because I wanted to compare without any currency impact so close to 60 000 in Q1 we had close to 40 000 previous quarter and quarter four previous year so that's a 48 percent close to 50 growth so that's growing in line with our expectations for the quarter however we are expecting a significant growth continuing going forward. Quickly then on cash position we ended the quarter with 65 million in cash and cash equivalents and the last financial slide as Anders said improving cash flow significantly 8 million Swedish kronor. This slide I have adjusted the change in working capital so comparing like for like because we had this reorganization in Q4 so we did quite a lot of payments on that accrued expenses in Q4 now in Q1 so the numbers that you have in the Q1 report look slightly different but at the end of the day it's 8 million improvement year over year on this one so with that I'll leave it over to Hector.

So see if we can get Hector in

the I am here but I'm exactly I think for you Helle you have to change to me right. Thank you thank you good morning good afternoon depending where you are I'm Hector Tamborini the of US operations based in San Diego California I'm going to share an overview of the first quarter of the fiscal year from the US perspective right now so as you heard says performance if you can go to the first slide second I mean this is the agenda we're going to review sales performance and few other topics so sales performance as you saw before we had a 48% growth in US dollars but that comes associated with a 20% growth in ordering institutions over the previous quarter which is very significant and encouraging and that also is accompanied by an increase in of 32% of new prescribers for Divitum this is extremely encouraging we're seeing the confidence and the trust that professionals put in our test so this is a really exciting time for the growth in the US if we go to the next slide one thing that we launched in this past quarter is a new initiative from the efforts that we put into spreading the knowledge of the test which is organizing advisory boards so we create sessions where one of the Divitum's early adopters and probably one of the most respected key opinion leaders we have shares their experience in terms of using Divitum as a treatment monitoring tool as well as a prognosis indicator this is based on real world cases on how thymidine kinase activity is a sensitive biomarker to monitor the patient's response to treatment and how it was used in these real cases to make decisions to improve patient response in some cases to reduce side effects of the medication and that is a very powerful message about the Divitum capabilities so one of the things that we enjoyed and observed was the active engagement of the attendees to these outboards we also obtained valuable feedback about you know the the breast cancer treatment from the patient's perspective as well as the physician's perspective which also allows us to craft and improve our messaging about Divitum we the the advantage of this sharing of experiences among oncologists is that resulted in additional prescribers interested in the test and we are already working with several that attended the boards are now are active prescribers if you could go to the next one thank you so going forward one of the initiatives that we are working on to accelerate growth is to grow the current accounts once we establish the relationship with an institution adding more prescribers from the institution is a fairly critical process for us because we already have that account working with us and there are many logistical aspects that are already in place also adding new accounts with a very laser focus on integrated delivery networks the big institutions that have not only the physicians but also they cover the patient's medication diagnostics etc so they are integrated and they have a vested interest in optimizing the use of that medication and Divitum is a critical tool for them and in all these cases one thing that we learn and we're working actively to to do is to reduce the administrative burden of ordering Divitum in some cases is simply working on the paperwork or the documentation needed the ultimate goal is to link the bio Vika laboratory information system which is our computerized system within the laboratory with the institution's electronical medical records so that's an easy process for the people ordering the test and the information being transferred to our lab I think we have one more basically showing something that I previously mentioned in our previous meeting the ongoing clinical trials we have several trials that are we're working as Anders Breilander mentioned with Yale University Washington in San Luis Missouri the Mayo Clinic and also the Hunterton Center in New Jersey all of them have clinical trials that will confirm the clinical utility of Divitum and potentially help us expand indications and one more slide where I want to share some of the work that we have right now in in the near term in December there's one of the largest breast cancer symposia it's called the San Antonio breast cancer symposium and there are six at least six abstracts that will be presented including Divitum and thymidine kinase activity test as a tool in the management of patients treatment and progression and that will provide an excellent forum to make the the test well known and well recognized by professionals we plan to have a in-person ad board or discussion panel with multiple attendees to the symposium where we can also discuss the the abstracts that are going to be presented and also have the possibility to engage new potential prescribers and out of the outcome of these abstracts we expect that there might be the the beginning of expansion into earlier phases of breast cancer the other activity for 2025 that we are working on is the inclusion in the NCCN guidelines the national comprehensive cancer network for breast cancer that's a very strong reference that physicians use and insurers use when a test is ordered or to order the test there is an extensive process we plan to apply for inclusion in 2025 and hopefully we think that all the clinical evidence clinical trials and real world experiences that we collected to to now will make as possible to qualify for this inclusion so that's a very strong support that would provide Divitum and an entry point into the prescription of the test and I think that's my presentation thank you for your attention to it and I'll pass it on to Rick right now so thank you go ahead.

Thank you very much so I'll provide you an update on what has happened you know during Q1 for the our pharma service business I'll start by saying that you know we continue in this part of our business to execute according to our strategy and according to our plan and this is really about onboarding more pharma companies and we do that by offering TKA service testing as well as kit sales and during Q1 we onboarded one new master service collaborator but we certainly also had several discussions with more companies and I'll come back to that on the next slide. Apart from onboarding pharma partners we also continue executing our work orders and we add more work orders and this together is of course what is driving our work order book and as you can see from the slide here by end of Q1 we had a work order book value which was 12.8 million Swedish and that's approximately 10 11 percent increase from last quarter even if you know we continue executing on the work order book so very positive. When we have you know onboarded these pharma partners what happens then is really that for several of these and after having executed on two three work orders for specific partners we start having discussions on a closer collaboration and currently you know the status there is that we have ongoing discussions with three pharmaceutical companies on a closer collaboration. All these companies are all within the drug field of CDK next generation and we also have a pilot study still running still evaluating results and still discussing the next steps within that pilot study. So if we dive deeper into the highlights of Q1 I mentioned that we have signed one MSA and it was PR back in late June but we also had two new MSA discussions in negotiations during the quarter and one is actually expected to be signed in very near future. Both of those MSAs are with pharmaceutical companies again working within the CDK next generation field. One is from US and one is from Europe. At the same time as we negotiate master service agreements we also discuss you know the initial work orders with these companies and with the US company we are actually speaking a very significant work order here. Then apart from from those new MSA negotiations we also amended an existing MSA with one or pharmaceutical companies and we amended that for another two and a half years. Then very exciting we signed an NDA with the tier one US company and we also initiated discussions with another tier one US company. So in those cases it's companies that want to add the TKA biomarker to their drug program portfolio and that is of course increasing the likelihood of being successful with a closer collaboration with these companies and ending up having companion MSAs together with tier one companies. Also UMQ1 mentioned by both Andes is that we had some postponement of activities. I just want to give a little more details here because it's not like that we didn't receive the samples. We actually did receive all the samples but we were not able to because of the high number we were not able to execute and also because of the time of the Q1 that we received the samples we were not able to complete the whole process and feedback to our customers before we were closing Q1. So yeah we did not completely reach what we had planned for in Q1 but we now see the highest month ever actually in August so you will see that and I think the August month is up approximately 300% compared to an average month when it comes to TKA service testing. So again emphasizing nothing about cancellation it's just a slight delay in the clinical trials at the final site. And then lastly a highlight also from the Q1 is that with the immune checkpoint inhibitor patent that we have been pursuing we're now moving into the national phase with that patent application and into those regions that we have selected as being important for our future. So by that

over to you Anders. Thank you Henrik. All right

to sum it up

so as I said initially we have a product that measures what's really essential in cancer. We believe that it has a very very strong potential and the belief is even stronger now when we've seen it in action in the clinic. We've seen now it's been used for about a year in the clinic in US and we see that it provides value to the practicing physicians that they can act changing dosing changing therapy schedules improving the treatment outcome for the patient is our ambition and vision and we're definitely seeing that we are on the right track there. The Q1 progress that we've been talking about we see sales development in US we see it in the pharmaceuticals as well not in revenues but on other KPIs. We've improved the cash flow and we've strengthened our financial position with the direct issue. Long term we have still our goal to become cash flow positive on the second half of 2025. In order to do that we need to increase our revenues significantly 35 million swedish per quarter versus the 1.7 that we have this quarter. So there's a of course a huge challenge but at the same time we also have laid a good foundation. We have organic growth in both the US and the pharma service actually in Europe also but it's later than the first two areas and we are confident that we can continue that but on on top of that we need to add agreements that can accelerate the growth further with significant steps and we are in discussions both within US and pharma which we have the ambition to close in the near future in order to further accelerate and reach that goal of becoming cash flow positive. And by doing so I'm certain that we can create significant value for first and foremost for the patients being treated for their cancer but also to all investors and shareholders that has invested in BioVika. So with that I'd like to open up for questions and let's do it this way we start with Johan and then go to Pareto and then Kempen. Great,

thank you for taking our questions. We can start off with the clinical IVD sales what about the progress in the pipeline and the disability ahead of course you have already delivered very healthy growth but still from rather modest absolute levels.

Yeah that's true could you elaborate a little bit you want on the question the what do you want me to address?

The visibility and the pipeline of additional clinics and patients and also the prospect of taking a larger substantial leap forward.

Yes, all right so maybe I can start and maybe you can follow on Hector if I missed something but so yeah we've laid a good foundation you could say we have now almost 30 of institutions that are ordering our test on a regular basis but however there's a great potential of increasing the number of prescribers per institution there's only one or two basically on average on every institution that is ordering so we have reached out to the early adopters that are interested in the new technology and together with them they have been using this and we see some excellent patient cases that we are elaborating can present in advice boards etc and we can also see that the test is working very well in the clinic which is of course super important. What we're doing now is we're building on this evidence and we're reaching out to institutions or oncologists and positions institutions that has the ambition to treat to implement this as a standard so we can grow within the existing institution and also our strategy rather than as we previously said we're looking for 10 client bill we are focusing on client bill accounts where we can accelerate and implement usage for that entire institution so thereby taking getting a more aggressive growth. A very good example of that has turned out to be the IDNs and there's an extra factor there which Hector talked about which is the health economic economy because the IDNs they don't only provide the service healthcare service but also the coverage the insurance for the patients so they have an extra interest in the health economics and then there's obvious demand for product like ours that can make some decisions not only for the patient but also financial health economics so that's the strategy to be a little bit more targeted on those accounts where we can identify people that with the evidence that we created that we can create the more aggressive growth. I hope I answered your question Joanne was that what you were looking for?

Yeah more or less perhaps is it possible to give a flavor for the pipeline of sort of reasonably near term IDN contracts?

Maybe Hector if you could just describe like the type of IDNs that we've been interacting with without giving away the names of course because it's still confidential but the characteristics we could I guess disclose.

Yes so Joanne I hope I can address your question so there are several organizations in the US that function as integrated service delivery to the patient so they almost provide an insurance so the patient subscribes to their insurance service and that allows them to access to the service by the physicians and all related services. They also have pharmacies so they provide the drug supply to the patient they also provide all the diagnostics tools that they need imaging, blood testing etc or laboratory services so for them having tools that allow to make the most efficient use of how they allocate those resources could be an extremely good tool and this is what we are trying to educate them educate the physician on how to use divitum. We know for instance that in many cases a patient treated with a certain CDK46 inhibitor will develop side effects and those side effects are extremely uncomfortable. Many patients go to the doctor and say please put me on something else because I can't tolerate this drug. The use of divitum could allow in some cases hopefully in many but not always the physician to follow the reduction in dose and use still an effective medication without the side effects and this is where we can integrate the services that these networks can provide because they're interested in keeping the patient keeping the patient in an effective medication but not wasting money or dropping treatments that are not effective and that's where we see a lot of potential for divitum. We were using some institutions some of these integrated networks as case studies because we're learning and they're learning from us but we expect to expand down the line to others that exist in different areas of US and they are regional in some cases you have some on the west coast you have some on the some of the states on the eastern east coast that are extremely significant.

Thank you Hector if I might add also status right now is that we have some of these actually starting using the test to validate it and has received good results and the next step for us is to close agreements and agree on usage on a wider scale.

Great thanks and on the pharma side then of course this was a bit of a low delivery quarter in terms of RUO services and kids what about prospects then Tor Winter alluded to that it's already clear that August is a step up what about the outlook?

Let Henrik in and let him elaborate a little bit about the pharma services portfolio where we stand and what you can expect.

Yeah thanks yeah so as I mentioned it was really you know few samples no few trials two trials and the samples from those two trials that were pushed into August and hence as I also said August is really was really promising because it's up 300 percent as compared to indeed an average month when it comes to the service testing. So service testing has really increased lately we have kickstarted several of you know the bigger work orders now with some of the bigger partners so it is looking very promising that way and on top of that having an extra master service agreement that is actually also the one we signed back in June is kicking off now in this month with the work order and two master service agreements in negotiations one close to finalization and also with the start in November December with samples so it's very promising on the testing piece when it comes to the kid sales it's a little bit more unpredictable but it's still you know kind of dictated by pharma because it's pharma using CROs and CROs buying our kids so we have you know we are very happy you know with the progress we've had so far and especially on the service testing piece because that is growing significantly.

Thank you and finally then it's interesting to hear that you are in discussions then regarding a potentially pharma collaboration or commercial partner regarding companion diagnostics

and what about the sorry yeah if I could add to that what you're saying and what Hendrik said we've already in the past reported that we have the majority of companies that are developing the new generation of CDK inhibitors that area is expected to have revenues depending on the analysts of 40 to 50 billion US dollars about 10 years from now so it's an extremely interesting and attractive market to be part of and also to support pharma to be competitive on that market and of course if you look at so we've added to a few or two tier two and tier three that we have signed and now we are in discussion with the additional tier ones and especially the tier ones we have three since before those are the one that really increased the probability for achieving CDK companion diagnostic collaboration deals CDK and CDX is very similar so that's why when Henrik says he's extremely happy with the development that's also because we are closing in to that agreement with the partners that we are discussing with now or the companies that we're discussing with now sorry for that.

Great thank you and finally then what about the prospect of commercial partners on the clinical side?

Yes on the clinical side we communicated that we would look into the possibilities I think we've received some positive feedback there as well and I think what would really really improve our attractiveness for such a deal with a big diagnostic company is to continue what we're doing growing revenues proving the commercial potential and also adding data that were complementary or even superior to ctdna in this application monitoring which we have since before in the from the bio italy but to strengthen that and also strengthen the documentation the data that we have potential outside of the metastatic breast cancer area and as hector said there's a lot of good abstracts coming up by end of year so it's looking good there as well.

Great thank you. Good thank you Jan. If we move on to Pareto I

don't Hi everyone. Good to

listen to the update and good progress considering the size you have. Just a question that came up during the call now is regarding august you mentioned 300 percent on a average quarter looking at some numbers here and up somewhere between four to six million steps or did I look at something wrong here?

You want to just so

I want some more direction on the services fee for august Henrik.

Service fee?

It is on page nine in the report there's a breakdown down of the fees.

Yes but regarding august and Henrik made the comment that it's 300 up on an average quarter so

and this

quarter wasn't an average quarter I guess so it's a bit a lot of unclear.

Yeah well I think we need to be to to wait until we give the next we will wait to to give exact numbers on to the next quarter report but you could say like this we had if you look at our average quarter we had for q4 for instance the majority of the revenues was from the pharma services so it was a stronger quarter even than the q1 so average quarter is typically stronger than this q1 where we had delay or revenues pushed forward yeah so that gives you some guidance.

So it would not be wrong to take that q4 where it was six and a half million divided by three for three months you end up a bit over two and then you add 300 on that you end around six million.

Very detailed here but it sounds like a good approach yes.

Okay interesting thank you and congrats on that. Are there any further cost reductions expected now going forward or can we assume that this is now a bit constant burn that you have going forward?

You can assume that this is a constant constant burn and we're able to increase revenue with this more efficient organization so that's our focus.

Okay great thank you and regarding the US sales are there any indications that you see a pickup of sales that would cross a few million sec in the coming quarters?

Yes that's definitely our ambition so if we're at the goal in like 15 months from now to have a 35 million sec per quarter we need to pick up we need to increase the growth rate versus the quarters leading up to this quarter just do the math you will see that and the way we think we'll be able to do that is that we believe we can continue and increase the organic growth component but we will add agreements that will accelerate with bigger where we can instead of grinding taking a prescriber per prescriber actually be able to get an implementation on one big institution that's the ambition to drive their growth and that's also where we are in discussion with both IDNs and some institutions that want to apply it as a standard marker for that institution.

Okay thank you and just getting back to the pharma sales that seems to have also picked up now after this quarter do you expect that then to continue or was this august just a very kind of outlier or do you see that this is continuing a little

same it's a little bit the same mechanics there as well as within the US sales so we have an underlying organic growth we are signing more and more both master services agreement and then leads to more work order and existing customers implemented on more and more of their clinical trials becoming more of a standard marker so that will continue if you pull that organic growth and the big game changer also which we expect within the the coming 15 months until that break even milestone is to sign an agreement that is a co-development for a companion diagnostic product that could have the same accelerating factor which will yeah lead to a bigger deal with quicker to bigger revenues. Henrik has given guidance in previous calls and in investor meetings on exactly how we see that such a product structured.

Okay thank you very much I think that is all from me thank you.

Thank you Dan.

Luisa. Yes hi team thank you for taking my questions maybe the first one on you mentioned the inclusion of divotum in the NCCN guidelines could you elaborate here a bit more on what are the steps necessary also in terms of timelines what is the usual process?

Maybe Hector if you want to do that or

yes and yeah I can do that so hi Luisa yeah I I'm I'm we're we're at the beginning of the process but basically there is a very first of all there is a set time when we can apply each area within the guidelines has a set time or dates that they accept the application I think we're looking at Q2 2025 for for breast cancer we have to prepare an extensive list of questions that we need to respond gather clinical trials clinical evidence of the test and how it's being used and this is a process that we are beginning right now hopefully gathering all this information and we will rely probably on input from some of our key opinion leaders when we need input from them but it will take us a couple of months to get all organized to apply and then send the application into the the organization

okay very clear thank you and in regards to well other inflection points until year end so until the end of this year and what can we get what can we expect in terms of inflection points so how many more distribution agreements in europe farm agreements so that kind of uh events all

right so uh

for the remnants of this year you can expect to see especially uh agreements on on the u.s markets market uh is what's uh closest and and also agreements within the pharma master services agreement in the coming months

okay thank you so much that's all from our side thank you all right

we have only one question actually uh from the web and uh the question is about the the increase of subscribers can you elaborate a little bit hector in absolute numbers uh number of prescribers uh currently using the test

so the question is how many prescribers are using the test currently

yeah the number of it says subscribers but i think i mean prescribers are using prescribers

yes yes yes and and we we use that term because in some depending on the state uh not only physicians can prescribe test in some cases uh nurse practitioners or physician assistants can prescribe and we've seen even though in a smaller percentage but we've seen some of them especially in offices that share the treatment of the patient between one or two professionals um we are right now in the range of over 30 active prescribers um some of them are really active uh have uh incorporated the test into their practice and they have the majority or a big proportion of the test that we process currently but right now we are i believe it's the number is 33 i don't want to give you the wrong number because that changes on a weekly basis but uh that's the range where we are right now

yeah all right

i

think that that was this it

for for this session thank you all for for calling in and thank you for the excellent questions so say thank you and over and out from By Weekend